Contract 75A50122C00047

Emergent Biodefense Operations Lansing Llc · Department Of Health And Human Services · August 26, 2022

Firm Fixed PriceSole SourceNAICS 541714

Emergent Biodefense Operations Lansing Llc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on August 26, 2022 for $211.41 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in Durham, NC. It was awarded under full and open competition. The contract has been modified 8 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on April 21, 2026. If all options are exercised, the contract could reach $647.49 million.

Obligated to date
$211.41M
$211,409,788
Current value
$211.41M
Potential value
$647.49M
if all options exercised
Modifications
8
Latest April 21, 2026

Contract details

PIID
75A50122C00047
Award type
Definitive Contract
Pricing
Firm Fixed Price
Set-aside
No Set Aside Used.
Competition
Not Competed
NAICS
541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
Product / service
General Science & Technology R&D Svcs; General Science & Technology; R&D Facilities & Maj Equip
Place of performance
Durham, NC
First action
August 26, 2022
Latest action
April 21, 2026

Description

THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE UEI FROM JLLWGQX6LNA5 TO MUM1EGCDWZJ4.

Modification timeline

  • April 21, 2026
    Mod P00008
    $0
  • September 5, 2025
    Mod P00007
    THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE CLIN0004B IN THE AMOUNT OF $17,104,200 FOR 40,000 TREATMENT COURSES OF ORAL SUSPENSION TEMBEXA AND UPDATED ARTIC
    $17.10M
  • December 12, 2024
    Mod P00006
    CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL - ADD 52.204-14 CLAUSE TO THE CONTRACT
    $0
  • September 19, 2024
    Mod P00005
    CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL
    $67.40M
  • March 19, 2024
    Mod P00004
    CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL
    $0
  • March 29, 2023
    Mod P00003
    CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL
    $0
  • December 16, 2022
    Mod P00002
    CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL
    $0
  • September 8, 2022
    Mod P00001
    CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL
    $0
  • August 26, 2022
    Base award
    CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL
    $126.90M

Similar contracts

RecipientAgencyDateObligated
Vericel CorporationDepartment Of Health And Human ServicesApril 1, 2026$34.88M
Ceramedix Holding, LlcDepartment Of Health And Human ServicesMarch 31, 2026$4.22M
American College Of Medical Toxicology, Inc.Department Of Health And Human ServicesMarch 31, 2026$0
Glaxosmithkline, LlcDepartment Of Health And Human ServicesMarch 31, 2026$7.79M
Care Access Research LlcDepartment Of Health And Human ServicesMarch 31, 2026$2.55M
Pattern Bioscience, Inc.Department Of Health And Human ServicesMarch 31, 2026$22.50M

Top contractors in NAICS 541714

Lifetime obligated dollars across all federal contracts in this NAICS code.

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract 75A50122C00047?

Contract 75A50122C00047 is a federal contract awarded to Emergent Biodefense Operations Lansing Llc by Department Of Health And Human Services on August 26, 2022 for $211.41 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 8 times since the base award.

Who won contract 75A50122C00047?

Emergent Biodefense Operations Lansing Llc won contract 75A50122C00047 from Department Of Health And Human Services.

How much is contract 75A50122C00047 worth?

Contract 75A50122C00047 has obligated $211.41 million to date, with a total potential value of $647.49 million if all options are exercised.